Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new platform called SPARCS is letting scientists screen tens of millions of genetically modified cells using AI and microscopy — at once. Developed by researchers across three German institutions, it links genetic changes to visible cellular effects and isolates cells of interest for deeper analysis. Early experiments revealed new genes involved in cellular recycling and immune signaling.
Scientists from LMU Munich, the Max Planck Institute of Biochemistry, and Helmholtz Munich have unveiled SPARCS — a platform that fuses artificial intelligence with large-scale microscopy and genetic screening. The tool can analyze millions of genetically modified cells, identify complex visual changes, and physically isolate individual cells for further study, all in one workflow. Results were published in the journal Cell.
In their proof-of-concept experiments, the team used SPARCS to scan 70 million cells for genetic effects on two key biological processes. For autophagy (the cell's internal recycling system), SPARCS confirmed known regulatory genes while also uncovering new ones. In a separate experiment focused on STING — a critical innate immune sensor — the team discovered that the acidity of the Golgi apparatus plays a key role in STING's early transport, with the protein GPHR acting as a regulator of that pH level.
Key Takeaways:
Why it matters: SPARCS could dramatically accelerate how researchers map gene function to cell behavior — a foundational step for understanding disease mechanisms and identifying new therapeutic targets in immunology, oncology, and beyond.
